Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 10/20 | 0.54 |
| ▸ | IKBKB | O14920 | 9/20 | 0.53 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093365 | 0.85 | CHEK1 (0.73) | CHEK1IKBKBMAP3K7 | |
| SCHEMBL1383089 | 0.84 | CHEK1 (0.75) | CHEK1IKBKBMAP3K7 | |
| SCHEMBL7471787 | 0.79 | MAP3K7 (0.62) | CHEK1IKBKBMAP3K7 | |
| SCHEMBL4087548 | 0.77 | IKBKB (0.64) | CHEK1IKBKBMAP3K7 | |
| SCHEMBL4081523 | 0.76 | CHEK1 (0.63) | CHEK1IKBKBMAP3K7 | |
| SCHEMBL2457605 | 0.75 | IKBKB (0.53) | CHEK1IKBKBMAP3K7 | |
| SCHEMBL1385148 | 0.74 | CHEK1 (0.73) | CHEK1IKBKBMAP3K7 | |
| SCHEMBL4088607 | 0.73 | CHEK1 (0.74) | CHEK1IKBKBMAP3K7 | |
| SCHEMBL490614 | 0.72 | IKBKB (0.63) | CHEK1IKBKBMAP3K7 | |
| SCHEMBL1385004 | 0.71 | IKBKB (1.00) | CHEK1IKBKBMAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | IKBKE, IKBKG, IKBKB | CHEK1 1097/4885IKBKB 3/4885MAP3K7 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.